Benefit from convalescent plasma shown in COVID outpatient trial

By | May 9, 2022
Researchers have conducted a double-blind, multicentre, randomized, controlled trial, which is known as Convalescent Plasma to Limit SARS-CoV-2 Associated Complications Study to evaluate if early COVID-19 plasma treatment could reduce disease progression and, thereby, reduce hospitalization rate.